Trial reportEBioMedicine2026
A randomized, observer-blind, phase 1 study of immune responses to three human adenovirus type 26 vector-based vaccines.
Trial report in EBioMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdenovirus 26 (Ad26) vector-based vaccines have shown immunogenicity and safety in various infectious disease settings. However, the impact of each vaccine component (vector/insert) on the immune response has yet to be explored in a controlled setting across multiple vaccines.
methodsIn this randomised, observer-masked, multicentre phase 1 study, participants aged 18-59 years were assigned to receive one of three vaccine regimens: Ad26.COV2.S (5 × 10
findingsFrom October 2022-August 2023, 160 participants received a study vaccine (Ad26.COV2.S, n = 66; Ad26.RSV.PreF/Protein, n = 48; Ad26.ZEBOV, n = 46). Median age was 35·5 years. All vaccines were well tolerated. Across vaccines, cytokine levels peaked on Day 2 and returned to baseline by Day 8. Highest geometric mean increases were observed with Ad26.RSV.PreF/Protein vaccine, followed by Ad26.COV2.S and Ad26.ZEBOV. The Ad26.RSV.PreF/Protein vaccine elicited the most differentially expressed genes and proteins, while Ad26.ZEBOV had the fewest. All vaccines induced strong innate responses associated with innate and antiviral immunity, hallmarked by interferons. Transcriptional responses were consistent among vaccines, differing primarily in magnitude rather than genes expressed.
interpretationAll three vaccine regimens induced specific immunogenic responses, were well tolerated, and triggered strong innate and antiviral immunity responses within 2 days post-vaccination, with no distinct immune signature observed across vaccines per transcriptomics/proteomics analyses.
fundingThis study was funded by Johnson & Johnson.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.